Detectnet (copper Cu-64 dotatate)
Intravenous Vial (Ea)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: copper Cu-64 dotatate
Therapeutic class: Diagnostic Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Detectnet
Indications
No indications are available for this drug.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Copper Cu 64 Dotatate/Long-Acting Somatostatin Analogs
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Both somatostatin analogs and copper Cu 64 dotatate bind to the same somatostatin receptors (SSTR2), resulting in competitive inhibition.(1)
CLINICAL EFFECTS: Concurrent use of copper Cu 64 dotatate and somatostatin analogs may affect the results of the scan.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: In patients receiving somatostatin analogs, perform the image just prior to dosing with long-acting somatostatin analogs. For patients on long-acting somatostatin analogs, a washout period of 28 days is recommended prior to imaging. For patients on short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging.(1)
DISCUSSION: Both somatostatin analogs and copper Cu 64 dotatate bind to the same somatostatin receptors (SSTR2), resulting in competitive inhibition, which can affect the results of the scan.(1)
Copper Cu 64 Dotatate/Short-Acting Somatostatin Analogs
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: Both somatostatin analogs and copper Cu 64 dotatate bind to the same somatostatin receptors (SSTR2), resulting in competitive inhibition.(1)
CLINICAL EFFECTS: Concurrent use of copper Cu 64 dotatate and somatostatin analogs may affect the results of the scan.(1)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: In patients receiving somatostatin analogs, perform the image just prior to dosing with long-acting somatostatin analogs. For patients on long-acting somatostatin analogs, a washout period of 28 days is recommended prior to imaging. For patients on short-acting somatostatin analogs, a washout period of 2 days is recommended prior to imaging.(1)
DISCUSSION: Both somatostatin analogs and copper Cu 64 dotatate bind to the same somatostatin receptors (SSTR2), resulting in competitive inhibition, which can affect the results of the scan.(1)
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
- Lactation
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
Rare or Very Rare
- Anaphylaxis
- Angioedema
More Frequent
- Flushing
- Nausea
- Vomiting
Less Frequent
- Pruritus of skin
- Skin rash
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.